BENITEC BIOPHARMA INC (BNTC) Forecast, Price Target & Analyst Ratings
NASDAQ:BNTC • US08205P2092
11.75 USD
-0.37 (-3.05%)
At close: Mar 13, 2026
11.75 USD
0 (0%)
After Hours: 3/13/2026, 4:30:03 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BENITEC BIOPHARMA INC (BNTC).
Forecast Snapshot
Consensus Price Target
$25.70
+ 118.76% Upside
Next Earnings Forecast
Release DateMay 12, 2026
PeriodQ3 / 2026
EPS Estimate-$0.29
Revenue Estimate
ChartMill Buy Consensus
87.69%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$25.70
Upside
+ 118.76%
From current price of $11.75 to mean target of $25.70, Based on 13 analyst forecasts
Low
$18.18
Median
$24.48
High
$33.60
Price Target Revisions
1 Month
0.00%
3 Months
-3.08%
Price Target Summary
13 Wall Street analysts provided a forecast for the next 12 months for BNTC. The average price target is 25.7 USD. This implies a price increase of 118.76% is expected in the next year compared to the current price of 11.75.
The average price target has been revised downward by 3.08% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
87.69%
BNTC was analyzed by 13 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about BNTC.
In the previous month the buy percentage consensus was at a similar level.
BNTC was analyzed by 13 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-04 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-11-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-24 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-09-16 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-15 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-04-10 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-03-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-18 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-13 | Baird | Initiate | Outperform |
| 2024-12-03 | Guggenheim | Reiterate | Buy -> Buy |
| 2024-10-16 | Oppenheimer | Initiate | Outperform |
| 2024-10-14 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-09-30 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-09-12 | Guggenheim | Initiate | Buy |
| 2024-07-22 | Leerink Partners | Initiate | Outperform |
| 2024-06-13 | Piper Sandler | Initiate | Overweight |
| 2024-04-22 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-02-15 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-01-24 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023-09-26 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023-06-26 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 12, 2026
PeriodQ3 / 2026
EPS Estimate-$0.29
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q-18.83%
Number of Analysts8
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
14.10%
Next Earnings Summary
BNTC is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is -0.29 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 60K -40.00% | 70K 16.67% | 80K 14.29% | -100.00% | 20.42M | 25.775M 26.22% | |||
| EBITDA YoY % growth | N/A | N/A | N/A -4.82% | -25.092M -26.23% | -26.112M -86.13% | -36.248M 13.07% | 10.997M 130.34% | N/A | |
| EBIT YoY % growth | -13.6M -64.25% | -17.85M -31.25% | -19.08M -6.89% | -22.739M -17.87% | -35.847M -85.70% | -53.471M -28.03% | -67.578M -26.38% | -50.19M 25.73% | |
| Operating Margin | -22,666.67% | -25,500.00% | -23,850.00% | N/A | N/A | N/A | -330.94% | -194.72% | |
| EPS YoY % growth | -3.21 43.56% | -1.02 68.18% | -16.94 -1,561.08% | -5.32 50.66% | -1.27 82.42% | -1.19 19.37% | -1.10 7.57% | -0.97 11.24% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.29 -18.83% | -0.31 26.27% | -0.26 -18.23% | -0.31 -17.69% | 0.07 125.04% | 0.72 333.86% |
| Revenue Q2Q % growth | 25.5M | 76.602M | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -14.334M -40.69% | -15.616M 9.08% | -11.277M -15.04% | -11.84M 11.49% | -12.433M 13.26% | -13.054M 16.41% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
10.21%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
BENITEC BIOPHARMA INC / BNTC Forecast FAQ
What is the price target for BNTC stock?
13 analysts have analysed BNTC and the average price target is 25.7 USD. This implies a price increase of 118.76% is expected in the next year compared to the current price of 11.75.
When does BENITEC BIOPHARMA INC (BNTC) report earnings?
BENITEC BIOPHARMA INC (BNTC) will report earnings on 2026-05-12.
What are the consensus estimates for BENITEC BIOPHARMA INC (BNTC) next earnings?
The consensus EPS estimate for the next earnings of BENITEC BIOPHARMA INC (BNTC) is -0.29 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for BNTC stock?
The consensus rating for BENITEC BIOPHARMA INC (BNTC) is 87.6923 / 100 . This indicates that analysts generally have a positive outlook on the stock.